True North Therapeutics is a biotechnology company developing a pipeline of novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in diseases with high unmet need, including rare diseases. The company's lead drug candidate, TNT009, offers a novel approach for treating Complement-mediated diseases by selectively inhibiting a target in the Classical Complement pathway.
Market
Rare diseases
Location
South San Francisco,
California,
USA
Coinvestors
Baxter Ventures, MPM Capital, OrbiMed Advisors, SR One